U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Asia Stocks Pause as Tech Earnings, Fed Signals, and Dollar Weakness Drive Markets 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Bank of Canada Holds Interest Rate at 2.25% Amid Trade and Global Uncertainty 
Canada’s Trade Deficit Jumps in November as Exports Slide and Firms Diversify Away From U.S. 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 
Dollar Struggles as Policy Uncertainty Weighs on Markets Despite Official Support 
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.
